Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC by Lara, Matthew S., BS, Gubens, Matthew A., MD, Bacaltos, Bianca, MS, Daran, Lea, BA, Lim, Steffany L., BS, Li, Tianhong, MD, Gandara, David R., MD, Bivona, Trever G., MD, PhD, Riess, Jonathan W., MD, Blakely, Collin M., MD, PhD

Get full text